A new report conducted by the Moran Company, a Health Management Associates company, indicates that treatment of beneficiaries with opioid use disorder cost Medicare $33 billion in 2022. This analysis highlights the significant economic burden associated with opioid use disorder in the Medicare program, shining a light on the importance of passing the Alternatives to PAIN Act to increase access to non-opioid pain management therapies under Medicare Part D and prevent opioid addiction before it begins.
New Report Indicates Treatment of Beneficiaries with Opioid Use Disorder Cost Medicare $33 Billion in 2022
No categories
